data + articles · 5 listed
newest 2022spec sheet10 rows
MXiPr (methoxisopropamine) is a 1,2-diarylethylamine dissociative belonging to the same chemical family as diphenidine, methoxphenidine, and ephenidine. Compounds of this class act primarily as uncompetitive antagonists at the N-methyl-D-aspartate (NMDA) glutamate receptor, producing the detached, sedating, anesthetic-like dissociative state characteristic of ketamine and phencyclidine; several members also show appreciable affinity for the dopamine transporter and sigma receptors. As a recently emerged research chemical, MXiPr has been little studied directly, and its potency, pharmacokinetics, and toxicology are inferred largely from better-characterized diarylethylamines. Human experience is limited to informal user reports describing prolonged dissociative and stimulant-like effects.
- Dissociation and detachment
- Sedation
- Altered body sensation
- NMDA-antagonist diarylethylamine dissociative
- Disorientation and confusion
- Raised blood pressure
- Ataxia (loss of coordination)
- Risk of agitation at higher doses
Mechanism
MXiPr is a diarylethylamine and is presumed to act as a non-competitive (N-methyl-D-aspartate) -receptor , the shared mechanism of methoxphenidine and ephenidine; blocking the NMDA channel reduces excitatory glutamate transmission and produces dissociation. Because it is so lightly studied, its exact binding affinity and any secondary monoamine activity are not well characterized, so its mechanism is described conservatively by analogy to its better-known relatives.
receptor fingerprint
Presumed non-competitive antagonist
Safetyrisks and cautions, not medical advice
Diarylethylamine dissociatives can cause heavy sedation, disorientation, high blood pressure, and, at higher doses, agitation or unpredictable delirium-like states; some in this family have long, unpredictable comeups that tempt early redosing. Stacking with alcohol, benzodiazepines, opioids, or other depressants deepens sedation and can impair breathing. With potency essentially uncharted, the margin between a mild and an overwhelming dose is unknown. Not medical advice.
Subjective profileweighing the evidence above
Not worth it. Potency is essentially uncharted, the comeup in this family is slow enough to tempt early redosing, and mixing it with alcohol or benzodiazepines can impair breathing. There is no human safety data on this specific compound, only what its relatives do.
Resources
This entry is here for reference.
Research
- 2014first citedFrom PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs.
- 2022most recentArylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects
- 1.Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects
- 2.[Identification of Three Arylcyclohexylamines (MXPr, MXiPr, and DMXE) in Illegal Products]
- 3.Pharmacological characterizations of the 'legal high' fluorolintane and isomers.
- 4."Word of mouse": indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine.
- 5.From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs.
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is MXiPr related to MXP?
Yes, it belongs to the same diarylethylamine dissociative family as methoxphenidine (MXP) and ephenidine and is presumed to share their NMDA-blocking mechanism.
Why the caution about redosing?
Diarylethylamines can take a long time to come on, which makes people redose too early and end up far deeper than intended.
Is much known about it?
No. It is a rarely studied research chemical with almost no formal human pharmacology, so descriptions rely on its structural relatives.
Adverse effects
- Disorientation and confusion
- Raised blood pressure
- Ataxia (loss of coordination)
- Risk of agitation at higher doses